JP2025525308A5 - - Google Patents

Info

Publication number
JP2025525308A5
JP2025525308A5 JP2024571035A JP2024571035A JP2025525308A5 JP 2025525308 A5 JP2025525308 A5 JP 2025525308A5 JP 2024571035 A JP2024571035 A JP 2024571035A JP 2024571035 A JP2024571035 A JP 2024571035A JP 2025525308 A5 JP2025525308 A5 JP 2025525308A5
Authority
JP
Japan
Prior art keywords
composition according
cells
disease
ganglioside
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024571035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025525308A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/026541 external-priority patent/WO2024006414A1/en
Publication of JP2025525308A publication Critical patent/JP2025525308A/ja
Publication of JP2025525308A5 publication Critical patent/JP2025525308A5/ja
Pending legal-status Critical Current

Links

JP2024571035A 2022-06-29 2023-06-29 新規の脂質ナノ粒子組成物およびその使用 Pending JP2025525308A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263356557P 2022-06-29 2022-06-29
US63/356,557 2022-06-29
PCT/US2023/026541 WO2024006414A1 (en) 2022-06-29 2023-06-29 Have been novel lipid nanoparticle compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2025525308A JP2025525308A (ja) 2025-08-05
JP2025525308A5 true JP2025525308A5 (OSRAM) 2026-04-17

Family

ID=89381439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024571035A Pending JP2025525308A (ja) 2022-06-29 2023-06-29 新規の脂質ナノ粒子組成物およびその使用

Country Status (6)

Country Link
US (2) US12303569B2 (OSRAM)
EP (1) EP4547224A1 (OSRAM)
JP (1) JP2025525308A (OSRAM)
CN (1) CN119403544A (OSRAM)
AU (1) AU2023297939A1 (OSRAM)
WO (1) WO2024006414A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120948302A (zh) * 2024-05-13 2025-11-14 国立医药品食品卫生研究所 使用离心场流分级检测颗粒的方法
WO2025250539A1 (en) * 2024-05-29 2025-12-04 Cytodigm, Inc. Pharmaceutical composition comprising sialic acid for treating diseases related to the lung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291969A1 (en) * 2014-01-30 2015-10-15 Chromatin, Inc. Compositions for reduced lignin content in sorghum and improving cell wall digestibility, and methods of making the same
AU2020301161B2 (en) * 2019-06-25 2023-10-26 Gilead Sciences, Inc. FLT3L-Fc fusion proteins and methods of use
CN116568331A (zh) * 2020-10-05 2023-08-08 希托迪格姆公司 Siglec-结合剂的药物组合物

Similar Documents

Publication Publication Date Title
Lu et al. Nucleic acid drug vectors for diagnosis and treatment of brain diseases
Tseu et al. A review of different types of liposomes and their advancements as a form of gene therapy treatment for breast cancer
Zhang et al. A comprehensive review of small interfering RNAs (siRNAs): mechanism, therapeutic targets, and delivery strategies for cancer therapy
Meng et al. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source
Patel et al. A review: surface engineering of lipid‐based drug delivery systems
Wang et al. Nanostructured lipid carriers for MicroRNA delivery in tumor gene therapy
EP2549986B1 (en) Multi-compartmental macrophage delivery
Zhou et al. Targeted delivery of cisplatin-derived nanoprecursors via a biomimetic yeast microcapsule for tumor therapy by the oral route
Luo et al. Nanoplatform‐based in vivo gene delivery systems for cancer therapy
Merkel et al. Nonviral siRNA delivery to the lung: Investigation of PEG− PEI polyplexes and their in vivo performance
Xu et al. Facile hydrophobization of siRNA with anticancer drug for non-cationic nanocarrier-mediated systemic delivery
Xu et al. Development of “CLAN” nanomedicine for nucleic acid therapeutics
JP2022542389A5 (OSRAM)
Afrin et al. Oral delivery of RNAi for cancer therapy
Guo et al. Cancer nanomedicines in an evolving oncology landscape
Rahman et al. Nucleic acid-loaded lipid-polymer nanohybrids as novel nanotherapeutics in anticancer therapy
Khan et al. Lipid-based colloidal nanoparticles for applications in targeted vaccine delivery
Fang et al. Roles of exosomes as drug delivery systems in cancer immunotherapy: a mini-review
Parashar et al. Next-Generation Nucleic Acid Delivery: A Review of Nanobiosystemc Design and Applications
Li et al. Biomembrane-wrapped gene delivery nanoparticles for cancer therapy
WO2021016106A8 (en) Multilamellar rna nanoparticles
Puccetti et al. Engineering carrier nanoparticles with biomimetic moieties for improved intracellular targeted delivery of mRNA therapeutics and vaccines
CN120676970A (zh) 用于核酸靶向递送的包含升高的天然脂质和靶向部分的脂质纳米颗粒
US20220347109A1 (en) Exosome-Mediated Transfection for Delivery of Nucleic Acids
Almalki et al. Advances in the polymeric nanoparticulate delivery systems for RNA therapeutics